Olmecor Hct (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmecor Hct, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination tablet for oral use. It is used to lower blood pressure in adults, often together with lifestyle measures. GNH USA supplies Olmecor Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmecor Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmecor Hct combines an ARB with a thiazide diuretic to treat hypertension through complementary mechanisms.

- Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - High‑risk cardiovascular patients: reduces the risk of stroke and heart attack as part of a comprehensive treatment plan. - Edema associated with hypertension: promotes fluid excretion while controlling blood pressure.

Olmecor Hct may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia or severe electrolyte imbalance - Angio‑edema involving the face, lips or tongue - Liver function abnormalities - Blood dyscrasias such as agranulocytosis

Before initiating Olmecor Hct, clinicians should evaluate patient history and monitor relevant parameters.

- Renal function: assess creatinine and eGFR before and during therapy. - Electrolytes: monitor potassium and sodium levels regularly. - Volume status: watch for signs of dehydration or excessive fluid loss. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant drugs: review for potential interactions, especially other antihypertensives. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmecor Hct can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): risk of severe hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: may cause dangerous hyper‑kalemia. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect kidney function. - Antidiabetic agents: may require dose adjustment due to enhanced glucose‑lowering effect. - Corticosteroids: can increase sodium retention, counteracting diuretic action.